AUTHORS
Wei LIU, Yi Wang, MD2, Huimin Liu3, Chenxing Du, MD4, Sisi Feng5, Pin Wang6, Lu-Gui Qiu, PhD7, Yarong Liu8, Dehui Zou, MD9
AFFILIATIONS
1 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
2 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
3 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 Grit Biotechnology, shanghai, China
6 Grit Biotechnology, shanghai, China
7 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
8 Grit Biotechnology, shanghai, China
9 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
ABSTRACT
Background
GT719 is an off-the-shelf chimeric antigen receptor natural killer T (CAR-NKT) cell therapy derived from umbilical cord blood hematopoietic stem cells. It is engineered to co-express an anti-CD19 CAR, an invariant NKT-specific T-cell receptor, and secreted interleukin-15 (IL-15). This design enables CD19-directed tumor killing, minimizes the risk of graft-versus-host disease (GVHD), and enhances cellular expansion, persistence, and immune function via IL-15 signaling. We conducted a phase 1, single-arm study (NCT06948981) to evaluate the safety and preliminary efficacy of GT719 in patients with relapsed or refractory (R/R) CD19-positive B-cell hematologic malignancies. Herein, we report preliminary data in 8 patients with R/R B-cell non-Hodgkin lymphoma (NHL).
Methods
Eligible participants had confirmed R/R CD19-positive B-cell hematologic malignancies. For NHL patients, failure of at least 2 lines of anti-CD20–containing therapy was required. Patients received either a single dose or three doses of GT719 following fludarabine and cyclophosphamide (FC) lymphodepletion. The primary endpoint was safety. Secondary endpoints included overall response rate (ORR), complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS).
Results
As of July 29, 2026, 8 patients with R/R B-cell NHL had been enrolled, including 1 with diffuse large B-cell lymphoma (DLBCL), 1 with high-grade B-cell lymphoma (HGBL) harboring MYC and BCL6 rearrangements, 3 with follicular lymphoma (FL) grade 3a, 2 with low-grade FL, and 1 with mantle cell lymphoma (MCL). At enrollment, 87.5% of patients had Ann Arbor stage III–IV disease, and 50% had bone marrow involvement. Patients had received a median of 3 prior lines of therapy, with 1 having relapsed after autologous stem cell transplantation. Following FC lymphodepletion, five patients received a single GT719 infusion (5×108 cells, n=2; 1×10? cells, n=3), and three received three infusions (5×108 cells on days 0, 7, and 14). Most adverse events (AEs) were Grade 1–2. Grade ≥3 AEs were limited to lymphodepletion-related cytopenias, which resolved or improved to Grade ≤2 within 14 days, excluding disease-related cytopenias. One patient experienced Grade 1 cytokine release syndrome, which resolved within 1 day. No cases of immune effector cell–associated neurotoxicity syndrome, neurotoxicity, GVHD, severe infections, or serious treatment-emergent adverse events were observed.
All eight patients were evaluable for efficacy. The ORR was 75%, with a CR rate of 50%. All 5 patients with R/R FL responded (ORR 100%), with 4 attaining CR (80%). At the last follow-up, 3 patients with R/R FL remain in ongoing CR, with the longest duration reaching 12 months. CAR transgene analysis demonstrated in vivo expansion of GT719, with peak levels occurring within 14 days post-infusion. GT719 persistence was observed for up to 9 months post-infusion.
Conclusions
GT719 exhibited a favorable safety profile and encouraging antitumor activity in adults with R/R CD19-positive B-cell NHL. The absence of severe GT719-related toxicities, together with evidence of in vivo expansion and durable cellular persistence, supports continued clinical investigation of this off-the-shelf CAR-NKT therapy.
DISCLOSURES
Wei LIU: No relevant conflicts of interest to declare.